Regeneron is expected to report Q1 2026 revenue of $3.41 billion and a consensus EPS of $8.36, with the current stock price of $751.57 trading below the $854.13 average analyst target. Investors are primarily focused on the commercial ramp of Eylea HD as it attempts to offset the double-digit decline of the legacy Eylea formulation due to intense competition from biosimilars and Vabysmo.
While Dupixent remains a robust growth driver with sustained momentum in multiple indications, Wall Street is also monitoring the company's emerging obesity pipeline following recent Phase 3 milestones. Management’s ability to defend gross margins amid this significant portfolio transition and the projected resolution of the Sanofi development balance are key themes for this quarter.